Grey Matters Launches US Brain PET Clinics for Alzheimer’s Diagnostics

Why It Matters

The clinics deliver essential diagnostic capability for emerging Alzheimer’s therapies, creating a new revenue stream and accelerating clinical trial enrollment while markedly improving patient experience.

Key Takeaways

• Grey Matters launches NovaScan PET clinics for Alzheimer’s diagnosis
• PET scans confirm amyloid plaques, essential for drug trial enrollment
• LOI with Catalyst MedTech secures 200 scans at Tampa clinic
• CareMiBrain scanner offers upright seating, 25% less radiation
• Targeting 162 Alzheimer’s drugs; 20% may need PET in Phase 2

Summary

Grey Matters Health announced the opening of its first U.S. brain PET imaging clinics, branded NovaScan, to provide amyloid plaque detection for Alzheimer’s diagnosis.

The company highlighted a letter of intent with Catalyst MedTech for at least 200 scans at its Tampa location, underscoring demand from contract research organizations that need PET confirmation for Phase 2 trials of Alzheimer’s therapeutics. With 162 drugs in development and roughly 20% expected to reach Phase 2, each scan commands $2,000+ in revenue.

CEO Christopher Moreau emphasized the patient‑centric CareMiBrain scanner, which allows upright seating and reduces radiation by 25% compared with conventional PET‑CT, improving comfort for elderly patients and expanding applicability to other neurodegenerative conditions.

If the rollout proceeds as planned—Davie clinic in Q3, Tampa in Q4, followed by a nationwide network—Grey Matters could emulate diagnostic giants like Simon Med and RadNet, positioning itself in a multi‑billion‑dollar market and potentially reshaping Alzheimer’s drug development pipelines.

Original Description

Grey Matters Health (CSE:GREY, OTCQB:AGNPD, FRA:AGW0) CEO Christopher Moreau joined Stephen Gunnion to discuss plans to launch NovaScan brain PET imaging clinics in Florida, targeting growing demand for Alzheimer’s diagnostics and clinical trials.

Moreau explained how PET imaging helps detect amyloid plaque linked to Alzheimer’s disease — something not possible with MRI or X-ray scans — making the technology increasingly important for diagnosis and treatment monitoring.

The interview also covered Grey Matters Health’s LOI with Catalyst MedTech for at least 200 scans at its planned Tampa clinic, as pharmaceutical companies expand Alzheimer’s drug trials.

Moreau highlighted the company’s CareMiBrain scanner, which allows patients to remain seated upright during scans while reducing radiation exposure by around 25%, offering what he described as a more comfortable alternative to traditional PET systems.

Grey Matters Health plans to expand its specialist imaging clinic network across the US as demand for neurological diagnostics grows.

For more videos like this, visit the Proactive YouTube channel, give this video a like, subscribe to the channel, and enable notifications for future content.

#GreyMattersHealth #Alzheimers #BrainPETScan #PETImaging #NovaScan #ChristopherMoreau #HealthcareInnovation #ClinicalTrials #Biotech #MedicalImaging #Neurology #AlzheimersResearch #HealthcareStocks #ProactiveInvestors